Pharmosa Biopharm Inc. (6875) Stock Statistics & Valuation Metrics
Total Valuation
Pharmosa Biopharm Inc. has a market cap or net worth of TWD 3.27B. The enterprise value is TWD 4.38B.
- Market Cap
- TWD 3.27B
- Enterprise Value
- TWD 4.38B
Share Statistics
Pharmosa Biopharm Inc. has 129,182,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 129,182,800
- Owned by Insiders
- ―
- Owned by Institutions
- 0.04%
Financial Efficiency
Pharmosa Biopharm Inc.’s return on equity (ROE) is -0.25 and return on invested capital (ROIC) is -24.16%.
- Return on Equity (ROE)
- -0.25
- Return on Assets (ROA)
- -0.22
- Return on Invested Capital (ROIC)
- -24.16%
- Return on Capital Employed (ROCE)
- -0.24
- Revenue Per Employee
- 4.48M
- Profits Per Employee
- -25.59M
- Employee Count
- 15
- Asset Turnover
- 0.04
- Inventory Turnover
- 4.19
Valuation Ratios
The current PE Ratio of Pharmosa Biopharm Inc. is -9.27. Pharmosa Biopharm Inc.’s PEG ratio is 0.18.
- PE Ratio
- -9.27
- PS Ratio
- 61.23
- PB Ratio
- 2.39
- Price to FCF
- -6.55
- Price to Operating Cash Flow
- -10.23
- PEG Ratio
- 0.18
Income Statement
In the last 12 months, Pharmosa Biopharm Inc. had revenue of 67.27M and earned -383.85M in profits. Earnings per share was -2.97.
- Revenue
- 67.27M
- Gross Profit
- -15.75M
- Operating Income
- -402.86M
- Pretax Income
- -383.85M
- Net Income
- -383.85M
- EBITDA
- -371.37M
- Earnings Per Share (EPS)
- -2.97
Cash Flow
In the last 12 months, operating cash flow was -319.30M and capital expenditures -179.93M, giving a free cash flow of -499.23M billion.
- Operating Cash Flow
- -319.30M
- Free Cash Flow
- -499.23M
- Free Cash Flow per Share
- -3.86
Dividends & Yields
Pharmosa Biopharm Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -15.27%
- Earnings Yield
- -10.75%
Stock Price Statistics
- Beta
- 0.33
- 52-Week Price Change
- -50.87%
- 50-Day Moving Average
- 29.62
- 200-Day Moving Average
- 35.34
- Relative Strength Index (RSI)
- 26.88
- Average Volume (3m)
- 151.99K
Important Dates
Pharmosa Biopharm Inc. upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 04, 2026
- Next Earnings Date
- Nov 18, 2026
- Ex-Dividend Date
- ―
Financial Position
Pharmosa Biopharm Inc. as a current ratio of 12.11, with Debt / Equity ratio of 6.39%
- Current Ratio
- 12.11
- Quick Ratio
- 11.91
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.43
- Interest Coverage Ratio
- -191.84
Taxes
In the past 12 months, Pharmosa Biopharm Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Pharmosa Biopharm Inc. EV to EBITDA ratio is -8.39, with an EV/FCF ratio of -5.76.
- EV to Sales
- 53.87
- EV to EBITDA
- -8.39
- EV to Free Cash Flow
- -5.76
- EV to Operating Cash Flow
- -9.01
Balance Sheet
Pharmosa Biopharm Inc. has TWD 933.28M in cash and marketable securities with TWD 340.88M in debt, giving a net cash position of TWD 592.39M billion.
- Cash & Marketable Securities
- TWD 933.28M
- Total Debt
- TWD 340.88M
- Net Cash
- TWD 592.39M
- Net Cash Per Share
- TWD 4.59
- Tangible Book Value Per Share
- TWD 10.57
Margins
Gross margin is -37.35%, with operating margin of -762.03%, and net profit margin of -658.14%.
- Gross Margin
- -37.35%
- Operating Margin
- -762.03%
- Pretax Margin
- -658.14%
- Net Profit Margin
- -658.14%
- EBITDA Margin
- -642.31%
- EBIT Margin
- -715.59%
Analyst Forecast
The average price target for Pharmosa Biopharm Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -69.26%
- EPS Growth Forecast
- -24.53%
